CD5 CAR-T Therapy(Xuanwu Hospital)

N/A

Report date: 2022/11/03 20:00:38

Base Information

Drug NameCD5 CAR-T Therapy(Xuanwu Hospital)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT-cell surface glycoprotein CD5 inhibitors

TargetsT-cell surface glycoprotein CD5

Therapy Area/IndicationsPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesXuanwu Hospital Of Capital Medical University

China Registration ClassN/A

Develop Information

Active CompaniesXuanwu Hospital Of Capital Medical University

Inactive CompaniesN/A

Active IndicationsPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A